Chronic insomnia has long been treated as a quality-of-life issue — disruptive, exhausting, but not medically dangerous in the way that conditions like hypertension or diabetes are. Research presented at the SLEEP 2026 Annual Meeting in Baltimore challenges that framing directly: multiple sessions at the conference converged on the finding that chronic insomnia is an independent cardiovascular risk factor, and that treating it with cognitive behavioral therapy for insomnia (CBT-I) produces measurable improvements in cardiovascular biomarkers.
The implication is significant. If insomnia treatment reduces blood pressure, cortisol, and inflammation — not just sleep complaints — then CBT-I is not merely a sleep intervention. It is a cardiac one.
The Biological Pathway From Insomnia to Heart Disease
The mechanistic link between chronic insomnia and cardiovascular disease centers on the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system. In chronic insomnia, both systems activate at night when they should be quiescent.
Elevated overnight cortisol and catecholamine levels suppress parasympathetic tone, raise resting heart rate, and over months and years contribute to vascular endothelial dysfunction. Inflammatory markers associated with atherosclerosis — including C-reactive protein and interleukin-6 — are consistently elevated in people with chronic insomnia compared to matched controls.
This is not simply a matter of short sleep duration. The SLEEP 2026 presentations emphasized that the hyperarousal state characteristic of insomnia — the inability to disengage the stress response at bedtime — drives cardiovascular risk through mechanisms distinct from those of voluntary sleep restriction.
CBT-I Reduces Cardiovascular Biomarkers
The most clinically actionable finding from SLEEP 2026 is that patients who completed CBT-I showed reductions in blood pressure, inflammatory markers, and cortisol patterns. This goes beyond self-reported sleep improvement; it represents objectively measured physiological change in systems directly linked to heart disease, stroke, and heart failure.
CBT-I is a structured, typically 6- to 8-session program that addresses the behavioral and cognitive patterns perpetuating insomnia. It includes sleep restriction, stimulus control, cognitive restructuring, and sleep hygiene education. Unlike sleeping pills, its effects persist long after treatment ends — multiple trials show durable improvements at 12-month and even 24-month follow-up.
The cardiovascular data add a new dimension to the argument for CBT-I as first-line insomnia treatment. Every major sleep medicine society already recommends it over medication. If CBT-I also reduces cardiac risk, the case for making it widely accessible becomes a public health imperative.
A Distinct High-Risk Subgroup
A related finding highlighted at the conference identified a subgroup of insomnia patients at particularly elevated cardiovascular risk: those who experience both excessive daytime sleepiness and prolonged sleep-onset latency. According to Dr. Alexandros Vgontzas, who presented the data, this combination may represent a physiologically distinct insomnia phenotype with significantly greater cardiovascular burden than other insomnia presentations.
This distinction matters for primary care. Not all insomnia patients carry the same cardiac risk, and identifying the highest-risk phenotype could help clinicians prioritize treatment referrals.
The Access Problem
The gap between the evidence for CBT-I and its availability remains wide. Fewer than 1% of primary care patients with insomnia receive CBT-I, according to estimates from the American Academy of Sleep Medicine. There are not enough trained therapists to meet demand, and many insurers do not cover the treatment.
Digital CBT-I programs — including SleepioRx, which received FDA clearance as a prescription digital therapeutic — were discussed at SLEEP 2026 as a scalable solution. Multiple studies have shown digital CBT-I to be as effective as in-person therapy for improving sleep outcomes. Whether the cardiovascular benefits observed with therapist-delivered CBT-I extend to digital formats is an active area of investigation.
What This Means for Patients
If you have chronic insomnia — difficulty sleeping three or more nights per week for three or more months — the SLEEP 2026 data suggest that treating it may do more than help you sleep. It may lower your blood pressure, reduce systemic inflammation, and decrease your long-term risk of heart disease.
The first step is asking your doctor about CBT-I rather than accepting a prescription for sleeping pills. If a trained CBT-I therapist is not available in your area, FDA-cleared digital programs offer an evidence-based alternative. The research increasingly shows that treating insomnia is not optional self-care — it is cardiovascular prevention.
